Logo image of ENOV

ENOVIS CORP (ENOV) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:ENOV - US1940141062 - Common Stock

27.02 USD
-0.94 (-3.36%)
Last: 12/5/2025, 8:16:21 PM
27.02 USD
0 (0%)
After Hours: 12/5/2025, 8:16:21 PM
Fundamental Rating

4

Taking everything into account, ENOV scores 4 out of 10 in our fundamental rating. ENOV was compared to 187 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of ENOV while its profitability can be described as average. ENOV scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year ENOV was profitable.
ENOV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
ENOV Yearly Net Income VS EBIT VS OCF VS FCFENOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M

1.2 Ratios

ENOV's Return On Assets of -30.84% is in line compared to the rest of the industry. ENOV outperforms 43.39% of its industry peers.
ENOV has a Return On Equity of -67.66%. This is comparable to the rest of the industry: ENOV outperforms 46.03% of its industry peers.
ENOV has a better Return On Invested Capital (0.12%) than 65.61% of its industry peers.
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROIC 0.12%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ENOV Yearly ROA, ROE, ROICENOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

Looking at the Operating Margin, with a value of 0.25%, ENOV is in the better half of the industry, outperforming 65.61% of the companies in the same industry.
ENOV's Operating Margin has declined in the last couple of years.
ENOV has a Gross Margin (57.19%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ENOV has grown nicely.
Industry RankSector Rank
OM 0.25%
PM (TTM) N/A
GM 57.19%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
ENOV Yearly Profit, Operating, Gross MarginsENOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ENOV is destroying value.
The number of shares outstanding for ENOV has been increased compared to 1 year ago.
The number of shares outstanding for ENOV has been increased compared to 5 years ago.
The debt/assets ratio for ENOV is higher compared to a year ago.
ENOV Yearly Shares OutstandingENOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENOV Yearly Total Debt VS Total AssetsENOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

ENOV has an Altman-Z score of 0.78. This is a bad value and indicates that ENOV is not financially healthy and even has some risk of bankruptcy.
ENOV has a Altman-Z score (0.78) which is in line with its industry peers.
ENOV has a debt to FCF ratio of 59.72. This is a negative value and a sign of low solvency as ENOV would need 59.72 years to pay back of all of its debts.
ENOV has a better Debt to FCF ratio (59.72) than 68.25% of its industry peers.
ENOV has a Debt/Equity ratio of 0.66. This is a neutral value indicating ENOV is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.66, ENOV is doing worse than 63.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Altman-Z 0.78
ROIC/WACC0.02
WACC7.23%
ENOV Yearly LT Debt VS Equity VS FCFENOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

ENOV has a Current Ratio of 2.22. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.22, ENOV is in line with its industry, outperforming 41.80% of the companies in the same industry.
A Quick Ratio of 1.16 indicates that ENOV should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.16, ENOV is doing worse than 70.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 1.16
ENOV Yearly Current Assets VS Current LiabilitesENOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.14% over the past year.
The earnings per share for ENOV have been decreasing by -16.18% on average. This is quite bad
Looking at the last year, ENOV shows a quite strong growth in Revenue. The Revenue has grown by 11.57% in the last year.
The Revenue has been decreasing by -8.73% on average over the past years.
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%

3.2 Future

Based on estimates for the next years, ENOV will show a very strong growth in Earnings Per Share. The EPS will grow by 23.19% on average per year.
The Revenue is expected to grow by 8.87% on average over the next years. This is quite good.
EPS Next Y14.56%
EPS Next 2Y11.4%
EPS Next 3Y11.38%
EPS Next 5Y23.19%
Revenue Next Year7.42%
Revenue Next 2Y5.98%
Revenue Next 3Y5.8%
Revenue Next 5Y8.87%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENOV Yearly Revenue VS EstimatesENOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B
ENOV Yearly EPS VS EstimatesENOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 8.11, which indicates a very decent valuation of ENOV.
Compared to the rest of the industry, the Price/Earnings ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 96.30% of the companies listed in the same industry.
ENOV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.49.
With a Price/Forward Earnings ratio of 7.69, the valuation of ENOV can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 97.88% of the companies listed in the same industry.
ENOV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.69.
Industry RankSector Rank
PE 8.11
Fwd PE 7.69
ENOV Price Earnings VS Forward Price EarningsENOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

ENOV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ENOV is cheaper than 92.06% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ENOV is valued a bit cheaper than the industry average as 71.96% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 67.88
EV/EBITDA 9.65
ENOV Per share dataENOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y11.4%
EPS Next 3Y11.38%

0

5. Dividend

5.1 Amount

No dividends for ENOV!.
Industry RankSector Rank
Dividend Yield N/A

ENOVIS CORP

NYSE:ENOV (12/5/2025, 8:16:21 PM)

After market: 27.02 0 (0%)

27.02

-0.94 (-3.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners117.5%
Inst Owner Change-2.39%
Ins Owners1.2%
Ins Owner Change0.83%
Market Cap1.55B
Revenue(TTM)2.23B
Net Income(TTM)-1.37B
Analysts83.75
Price Target49.07 (81.61%)
Short Float %13.78%
Short Ratio10.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.55%
Min EPS beat(2)7.76%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)8.22%
Min EPS beat(4)4.97%
Max EPS beat(4)13.35%
EPS beat(8)8
Avg EPS beat(8)7.21%
EPS beat(12)12
Avg EPS beat(12)8.15%
EPS beat(16)16
Avg EPS beat(16)8.66%
Revenue beat(2)0
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-0.21%
Max Revenue beat(2)-0.09%
Revenue beat(4)0
Avg Revenue beat(4)-0.8%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.09%
Revenue beat(8)2
Avg Revenue beat(8)-0.81%
Revenue beat(12)4
Avg Revenue beat(12)-0.8%
Revenue beat(16)5
Avg Revenue beat(16)-4.71%
PT rev (1m)-7.03%
PT rev (3m)-11.45%
EPS NQ rev (1m)-0.37%
EPS NQ rev (3m)-5.55%
EPS NY rev (1m)1.75%
EPS NY rev (3m)1.73%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE 8.11
Fwd PE 7.69
P/S 0.69
P/FCF 67.88
P/OCF 7.12
P/B 0.76
P/tB N/A
EV/EBITDA 9.65
EPS(TTM)3.33
EY12.32%
EPS(NY)3.51
Fwd EY13%
FCF(TTM)0.4
FCFY1.47%
OCF(TTM)3.8
OCFY14.05%
SpS39.05
BVpS35.33
TBVpS-8.37
PEG (NY)0.56
PEG (5Y)N/A
Graham Number51.45
Profitability
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.12%
ROICexgc 0.34%
OM 0.25%
PM (TTM) N/A
GM 57.19%
FCFM 1.02%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-45.54%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.8%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Debt/EBITDA 4.5
Cap/Depr 66.6%
Cap/Sales 8.7%
Interest Coverage 250
Cash Conversion 72.98%
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 1.16
Altman-Z 0.78
F-Score4
WACC7.23%
ROIC/WACC0.02
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
EPS Next Y14.56%
EPS Next 2Y11.4%
EPS Next 3Y11.38%
EPS Next 5Y23.19%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%
Revenue Next Year7.42%
Revenue Next 2Y5.98%
Revenue Next 3Y5.8%
Revenue Next 5Y8.87%
EBIT growth 1Y-35.24%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year76.5%
EBIT Next 3Y28.12%
EBIT Next 5Y28.11%
FCF growth 1Y122.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y609.06%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%

ENOVIS CORP / ENOV FAQ

What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ENOV.


Can you provide the valuation status for ENOVIS CORP?

ChartMill assigns a valuation rating of 8 / 10 to ENOVIS CORP (ENOV). This can be considered as Undervalued.


Can you provide the profitability details for ENOVIS CORP?

ENOVIS CORP (ENOV) has a profitability rating of 4 / 10.


What is the earnings growth outlook for ENOVIS CORP?

The Earnings per Share (EPS) of ENOVIS CORP (ENOV) is expected to grow by 14.56% in the next year.